CG Oncology reports 54% CR at 24 months for cretostimogene combo in NMIBC

CG Oncology, Inc.

Phase 2 CORE-001 final results: 54% (19/35) complete response rate at 24 months in BCG-unresponsive HR-NMIBC with CIS.
Median duration of response exceeds 21 months; 95% of 12-month CR patients maintained CR for another 12 months.
Progression-free survival at 24 months was 100%; cystectomy-free survival at 24 months was 80% (100% for CR patients).
No synergistic toxicity observed; combination with pembrolizumab well tolerated.
FDA Breakthrough Therapy Designation granted in May 2023; company plans to incorporate findings into planned CORE-008 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.